Sun Pharma to Invest $100M in Specialty Drug Launches This Fiscal

Key Highlights:

• Sun Pharma invests $100M in specialty product commercialization.
• Launching Leqselvi, Unloxcyt for alopecia, skin cancer treatments.
• Seeks partners for MM-II; GL0034 trial planned for diabetes.

According to Chairman and Managing Director Dilip Shanghvi, Sun Pharmaceutical Industries has secured a USD 100 million investment to commercialize innovative pharmaceuticals in the current fiscal year. The Mumbai-based pharmaceutical giant, the investment will greatly support the company's future specialty (patented product) sector."For the current year, we are looking to invest approximately USD 100 million additionally on the commercialisation of new speciality products," Shanghvi told analysts in a call.

The pharmaceutical company intends to make a significant investments in the introduction of two products: Leqselvi and Unloxcyt.Leqselvi is prescribed to treat adults with severe alopecia areata, whereas Unloxcyt is prescribed to treat adults with metastatic cutaneous squamous cell carcinoma. Shanghvi provided more details about the specialty product category, stating that it is currently looking for a partner to help develop and market MM-II (for osteoarthritis pain) in specific regions.

"This change is due to the strategic reassessment of our pipeline. We continue to believe in the potential of the product. Another change is that we are now planning a trial of GL0034 in type 2 diabetes as its first indication," he added.

Also Read: HN Reliance Launches Fastest AI 3D Mammography in South Asia

"We are awaiting approval of that transaction and subsequent closing. Checkpoint has recently received approval from USFDA for Unloxcyt for metastatic or locally advanced cutaneous squamous cell carcinoma and we look forward to leveraging our presence to accelerate patient's access to Unloxcyt," Shangvi said.